---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-301464"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2026-07-13T11:09:59+00:00"
generated_at: "2026-07-13T11:15:36.622199+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio: positive 36-week Phase 2a data for bempikibart in alopecia areata; registration trial planned H1 2027

## Summary
- Mean percent reduction in SALT score from baseline of 35.3% in mITT analysis at Week 36.
- 40% (10/25) mITT and 30.3% (10/33) ITT achieved SALT-20; 44% achieved SALT-30 and SALT-50.
- No serious adverse events or Grade 3+ treatment-related AEs; mild injection site reaction in 36.3% of patients (4% of doses).
- Company paid off remaining $6.8M loan to Silicon Valley Bank on June 24, 2026; loan agreement terminated.
- Plans to advance bempikibart into registration-directed program in first half of 2027.

## SEC filing metadata
- accession: 0001193125-26-301464
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2026-07-13T11:09:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312526301464/0001193125-26-301464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312526301464/d142528d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-301464
- JSON: https://secwatch.observer/filing/0001193125-26-301464.json
- Plain text: https://secwatch.observer/filing/0001193125-26-301464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.